Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1072 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 40, which is 13 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has average fundamentals. Bioventus has seen its stock return 36.43% over the past year, overperforming other healthcare stocks by 60 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 42.05% from Bioventus's current stock price of $10.56.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #2 top healthcare stock out of 1072 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: C, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 30, which is 3 points higher than the healthcare sector average of 27. It passed 10 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 82.01% over the past year, overperforming other healthcare stocks by 105 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $15.00, an upside of 14.94% from Amneal Pharmaceuticals's current stock price of $13.05.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Viemed Healthcare (NASDAQ:VMD) is the #3 top healthcare stock out of 1072 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Viemed Healthcare (NASDAQ:VMD) is: Value: C, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: B.

Viemed Healthcare (NASDAQ:VMD) has a Due Diligence Score of 59, which is 32 points higher than the healthcare sector average of 27. It passed 19 out of 33 due diligence checks and has strong fundamentals. Viemed Healthcare has seen its stock return 45.39% over the past year, overperforming other healthcare stocks by 69 percentage points.

Out of 73 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

So Young International (NASDAQ:SY) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.38%.

So Young International's dividend payout ratio of -7.6% indicates that its dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 21.73%, which is 19 percentage points higher than the healthcare sector average of 2.38%.

Dominari Holdings's dividend payout ratio of -42.4% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 12.77%, which is 10 percentage points higher than the healthcare sector average of 2.38%.

Siga Technologies's dividend payout ratio of 181.8% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.03% in the last day, and up 1.73% over the last week. Aspire Biopharma Holdings was the among the top losers in the healthcare sector, dropping -54.2% yesterday.

Aspire Biopharma shares are trading lower. The company announced a non-binding LOI to acquire 100% of driver controls systems business unit of Firefish Topco in a deal valued at $30 million.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 70 points higher than the healthcare sector average of 16. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -19.31% in the past year. It has overperformed other stocks in the healthcare sector by 4 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 1.63% in the past year. It has overperformed other stocks in the healthcare sector by 25 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 505.26% in the past year. It has overperformed other stocks in the healthcare sector by 529 percentage points.

58.58% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 36.91% over the next year.

6.04% of healthcare stocks have a Zen Rating of A (Strong Buy), 11.84% of healthcare stocks are rated B (Buy), 51.54% are rated C (Hold), 23.18% are rated D (Sell), and 7.4% are rated F (Strong Sell).